Background: The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognized, and hence reliable biomarkers are needed. Objectives: To investigate the prognostic role of cerebrospinal fluid (CSF) amyloid beta1–42 (Aβ) levels by the determination of a cut-off value to classify patients in slow and fast progressors. To evaluate possible association with white matter (WM) and grey matter (GM) damage at early disease stages. Methods: Sixty patients were recruited and followed up for 3–5 years. Patients underwent clinical assessment, brain magnetic resonance imaging (MRI; at baseline and after 1 year), and CSF analysis to determine Aβ levels. T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads. Results: Lower CSF Aβ levels were observed in patients with a worse follow-up Expanded Disability Status Scale (EDSS; r = −0.65, p < 0.001). The multiple regression analysis confirmed CSF Aβ concentration as a predictor of patients’ EDSS increase (r = −0.59, p < 0.0001). Generating a receiver operating characteristic curve, a cut-off value of 813 pg/mL was determined as the threshold able to identify patients with worse prognosis (95% confidence interval (CI): 0.690–0.933, p = 0.0001). No differences in CSF tau and neurofilament light chain (NfL) levels were observed (p > 0.05). Conclusion: Low CSF Aβ levels may represent a predictive biomarker of disease progression in MS.

CSF β-amyloid predicts prognosis in patients with multiple sclerosis / Pietroboni, A. M.; Caprioli, M.; Carandini, T.; Scarioni, M.; Ghezzi, L.; Arighi, A.; Cioffi, S.; Cinnante, C.; Fenoglio, C.; Oldoni, E.; De Riz, M. A.; Basilico, P.; Fumagalli, G. G.; Colombi, A.; Giulietti, G.; Serra, L.; Triulzi, F.; Bozzali, M.; Scarpini, E.; Galimberti, D.. - In: MULTIPLE SCLEROSIS. - ISSN 1352-4585. - 25:9(2019), pp. 1223-1231. [10.1177/1352458518791709]

CSF β-amyloid predicts prognosis in patients with multiple sclerosis

Fumagalli G. G.;
2019-01-01

Abstract

Background: The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognized, and hence reliable biomarkers are needed. Objectives: To investigate the prognostic role of cerebrospinal fluid (CSF) amyloid beta1–42 (Aβ) levels by the determination of a cut-off value to classify patients in slow and fast progressors. To evaluate possible association with white matter (WM) and grey matter (GM) damage at early disease stages. Methods: Sixty patients were recruited and followed up for 3–5 years. Patients underwent clinical assessment, brain magnetic resonance imaging (MRI; at baseline and after 1 year), and CSF analysis to determine Aβ levels. T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads. Results: Lower CSF Aβ levels were observed in patients with a worse follow-up Expanded Disability Status Scale (EDSS; r = −0.65, p < 0.001). The multiple regression analysis confirmed CSF Aβ concentration as a predictor of patients’ EDSS increase (r = −0.59, p < 0.0001). Generating a receiver operating characteristic curve, a cut-off value of 813 pg/mL was determined as the threshold able to identify patients with worse prognosis (95% confidence interval (CI): 0.690–0.933, p = 0.0001). No differences in CSF tau and neurofilament light chain (NfL) levels were observed (p > 0.05). Conclusion: Low CSF Aβ levels may represent a predictive biomarker of disease progression in MS.
2019
9
Pietroboni, A. M.; Caprioli, M.; Carandini, T.; Scarioni, M.; Ghezzi, L.; Arighi, A.; Cioffi, S.; Cinnante, C.; Fenoglio, C.; Oldoni, E.; De Riz, M. A.; Basilico, P.; Fumagalli, G. G.; Colombi, A.; Giulietti, G.; Serra, L.; Triulzi, F.; Bozzali, M.; Scarpini, E.; Galimberti, D.
CSF β-amyloid predicts prognosis in patients with multiple sclerosis / Pietroboni, A. M.; Caprioli, M.; Carandini, T.; Scarioni, M.; Ghezzi, L.; Arighi, A.; Cioffi, S.; Cinnante, C.; Fenoglio, C.; Oldoni, E.; De Riz, M. A.; Basilico, P.; Fumagalli, G. G.; Colombi, A.; Giulietti, G.; Serra, L.; Triulzi, F.; Bozzali, M.; Scarpini, E.; Galimberti, D.. - In: MULTIPLE SCLEROSIS. - ISSN 1352-4585. - 25:9(2019), pp. 1223-1231. [10.1177/1352458518791709]
File in questo prodotto:
File Dimensione Formato  
2018 Pietroboni et al beta amil prognosis mult scler.pdf

Solo gestori archivio

Descrizione: first online
Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 384.79 kB
Formato Adobe PDF
384.79 kB Adobe PDF   Visualizza/Apri
1352458518791709.pdf

Solo gestori archivio

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 374.1 kB
Formato Adobe PDF
374.1 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/355528
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 20
social impact